When a covalent inhibitor of CDK7 is used to disrupt the transcription of amplified MYCN in NB cells, the oncoproteins are downregulated with the consequent strong suppression of MYCN. THZ1 selectively targets MYCN-amplified NB cells, and THZ1 target treatment leads to the preferential downregulation of SE-associated genes and significantly represses MYCN-dependent transcriptional amplification68 (Table 2). Here, CDK7 is linked to neuroblastoma.